DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond
Joel N. Maslow, Ijoo Kwon, Sagar B. Kudchodkar, D. M. Kane, Amha Tadesse, Hyojin Lee, Young K. Park, Kar Muthumani, Christine C. Roberts
Abstract
We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines have significant advantages with regard to the rapidity of production, thermostability, safety profile, and cellular immune responses. Based on user needs and cost, we compare the three devices used in the SARS-CoV-2 clinical trials. Of the three devices, the GeneDerm suction device offers numerous benefits, particularly for international vaccination campaigns. As such, DNA vaccines represent a promising option for future pandemics.